Nivolumab (Opdivo) for
Cancer Treatment

Nivolumab, sold as Opdivo, is an immunotherapy medicine used in selected cancers where blocking the PD-1 immune checkpoint may help the immune system recognize and attack cancer cells. This page is for patients and families who have been advised to consider immunotherapy, are comparing treatment options after progression, or need a second opinion before starting nivolumab. CancerFax helps patients organize reports, check suitability, understand access pathways, and coordinate specialist review responsibly. Primary CTA: Share Your Reports. Secondary CTA: Speak to CancerFax.

Nivolumab usually becomes important when standard treatment has limited benefit, when a cancer type has an established immunotherapy role, or when biomarker results suggest that immune checkpoint treatment should be reviewed. It may be used alone or with other treatments in selected settings. A careful oncology review is essential because timing, combination choice and safety monitoring can strongly affect the treatment plan.

Families often search for Opdivo when cancer has progressed despite chemotherapy, when local options feel unclear, or when a doctor mentions immunotherapy but does not explain eligibility fully. The hope is understandable, but nivolumab is not suitable for every patient. CancerFax helps families move from uncertainty to a structured review of diagnosis, reports, previous treatment, biomarkers, possible access routes and practical next steps.

Nivolumab is a monoclonal antibody that blocks the PD-1 receptor. The National Cancer Institute describes it as a programmed death receptor-1 blocking antibody that prevents PD-1 from interacting with PD-L1 and PD-L2, helping release immune pathway inhibition against tumors. In simple terms, it does not directly kill cancer like chemotherapy. Instead, it may help immune cells recognize cancer more effectively. Because immune activation can also affect normal organs, treatment must be supervised by an oncologist experienced in immunotherapy.

Eligibility depends on cancer type, stage, pathology, immunohistochemistry, molecular or NGS results, previous therapies, current disease burden, symptoms, autoimmune history, organ function and fitness to travel if international care is being considered. Patients with uncontrolled autoimmune disease, severe organ dysfunction, active infection or rapidly unstable disease may need alternative planning. Suitability should never be assumed from the drug name alone; it requires specialist review and, in some cancers, biomarker confirmation.

A proper nivolumab suitability review usually needs a medical summary, biopsy or surgery pathology report, IHC report, PD-L1 result if performed, MSI/MMR report where relevant, NGS or molecular testing report, PET-CT, CT or MRI reports, recent blood tests, treatment history, discharge summaries, current medicines and the treating doctor’s latest opinion. If records are incomplete, CancerFax can help families understand which missing documents may be needed before hospital review.

CancerFax first helps collect and organize medical records, then understands the diagnosis, prior treatment and current clinical problem. The team can coordinate second opinions, suitability checks, hospital or specialist review, treatment-planning guidance, cost clarity, interpreter support, admission coordination and post-treatment communication. For international patients, CancerFax also helps families compare access pathways, likely timelines, stay requirements and documents needed before travel.

The cost of nivolumab treatment varies by country, hospital, dose schedule, whether it is approved treatment or part of a clinical trial, the number of cycles, required imaging, lab monitoring, management of side effects and length of stay. Some patients need only outpatient infusions, while others need admission because of complications or combination therapy. International planning should also include accommodation, travel, translation, caregiver stay and follow-up communication costs.

Nivolumab can cause immune-related side effects because it activates immune responses. These may affect the lungs, bowel, liver, kidneys, skin, hormone glands or other organs. Symptoms such as breathlessness, severe diarrhea, jaundice, persistent fever, confusion or sudden weakness require urgent medical attention. Results are not guaranteed, some cancers do not respond, and treatment can sometimes be stopped because of toxicity or progression. Final decisions must be made by qualified oncologists.

Nivolumab may be available through government cancer centres, university hospitals, private oncology hospitals and selected clinical trial units. Availability, brand access, biosimilar policies, cost, combination protocols and admission timelines vary between countries and centres. Patients considering care abroad should confirm whether the centre can review the exact cancer type, biomarker profile, previous treatments and safety risks before travel.

Frequently Asked Questions

Answers to common questions from patients and families.

If nivolumab has been suggested, or if you are unsure whether immunotherapy is still an option, share your reports with CancerFax. A structured review can help clarify whether Opdivo, another immunotherapy, targeted therapy, a combination approach or a clinical trial should be discussed with specialists.

[1] National Cancer Institute. Nivolumab (OPDIVO®). https://dctd.cancer.gov/drug-discovery-development/reagents-materials/formulary/about/agents/nivolumab [2] Bristol Myers Squibb. OPDIVO U.S. Prescribing Information. https://packageinserts.bms.com/pi/pi_opdivo.pdf

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.